Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14559606 | 1.00 | CYP1A2 (0.55) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL8348773 | 1.00 | CYP1A2 (0.55) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL14559584 | 1.00 | CYP1A2 (0.55) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL5390449 | 0.98 | ALDH1A1 (0.58) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Hydrochloric Acid SCHEMBL5384785 | 0.98 | CYP1A2 (0.53) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL14559594 | 0.96 | CYP1A2 (0.55) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL14559590 | 0.96 | CYP1A2 (0.55) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL5382165 | 0.96 | CYP1A2 (0.55) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Hydrochloric Acid SCHEMBL5381205 | 0.94 | CYP1A2 (0.53) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL7432467 | 0.93 | CYP1A2 (0.53) | CYP1A2ALDH1A1USP2LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1506955-B1 | Bicyclic amino acids as pharmaceuticals agents | WARNER LAMBERT CO (US) | 2007-03-28 | — | — | EP | claimed |
| CN-1678298-A | Use of an alpha2delta ligand such as gabapentin or pregabalin for treating ttention deficit hyperactivity disorder | WARNER LAMBERT CO (US) | 2005-10-05 | — | — | CN | claimed |
| CN-1610544-A | Method for preventing and treating visceral pain and gastrointestinal disorders | WARNER LAMBERT CO (US) | 2005-04-27 | — | — | CN | claimed |
| EP-1515709-A2 | USE OF AN ALPHA2DELTA LIGAND SUCH AS GABAPENTIN OR PREGABALIN FOR TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER | Warner-Lambert Company LLC (US) | 2005-03-23 | — | — | EP | claimed |
| EP-1514541-A1 | Use of bicyclic amino acids for preventing and treating visceral pain and gastrointestinal disorders | Warner-Lambert Company LLC (US) | 2005-03-16 | — | — | EP | claimed |
| EP-1506955-A1 | Bicyclic amino acids as pharmaceuticals agents | Warner-Lambert Company LLC (US) | 2005-02-16 | — | — | EP | claimed |
| US-20040266876-A1 | Method for preventing and treating visceral pain and gastrointestinal disorders | CHOVET MARIA (FR) | 2004-12-30 | — | — | US | claimed |
| CN-1165518-C | Bicyclic amino acids as pharmaceutical agents | ��ʲ | 2004-09-08 | — | — | CN | claimed |
| US-6784208-B2 | BICYCLIC FUSED HYDROCARBON RINGS SUBSTITUTED WITH AMINOMETHYL AND CARBOXYMETHYL GROUPS ON SAME POSITION OF RING; 3-AMINOMETHYL-BICYCLO(3.2.0)HEPTANE-3-ACETIC ACID FOR EXAMPLE | WARNER-LAMBERT COMPANY | 2004-08-31 | — | — | US | claimed |
| US-20040152779-A1 | Bicyclic amino acids as pharmaceutical agents | BRYANS JUSTIN STEPHEN (GB) | 2004-08-05 | — | — | US | claimed |
| WO-2004002462-A2 | USE OF AN ALPHA2DELTA LIGAND SUCH AS GABAPENTIN OR PREGABALIN FOR TREATING TTENTION DEFICIT HYPERACTIVITY DISORDER | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-08 | — | — | WO | claimed |
| EP-1357910-A2 | METHOD FOR PREVENTING AND TREATING VISCERAL PAIN AND GASTROINTESTINAL DISORDERS | Warner-Lambert Company LLC (US) | 2003-11-05 | — | — | EP | claimed |
| CN-1382118-A | Bicyclic amino acids as pharmaceutical agents | WARNER LAMBERT CO (US) | 2002-11-27 | — | — | CN | claimed |
| US-20020161047-A1 | Method for preventing and treating visceral pain and gastrointestinal disorders | WARNER-LAMBERT COMPANY | 2002-10-31 | — | — | US | claimed |
| WO-2002058680-A2 | USE OF BICYLIC AMINO ACIDS FOR PREVENTING AND TREATING VISCERAL PAIN AND GASTROINTESTINAL DISORDERS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-01 | — | — | WO | claimed |
| EP-1226820-A1 | Use of bicyclic amino acids for preventing and treating visceral pain and gastrointestinal disorders | WARNER-LAMBERT COMPANY (US) | 2002-07-31 | — | — | EP | claimed |
| EP-1226110-A1 | BICYCLIC AMINO ACIDS AS PHARMACEUTICAL AGENTS | WARNER-LAMBERT COMPANY (US) | 2002-07-31 | — | — | EP | claimed |
| US-20020072533-A1 | Method of treating cartilage damage | SCHRIER DENIS (US) | 2002-06-13 | — | — | US | claimed |
| EP-1199072-A2 | Method of treating cartilage damage | WARNER-LAMBERT COMPANY (US) | 2002-04-24 | — | — | EP | claimed |
| WO-2001028978-A1 | BICYCLIC AMINO ACIDS AS PHARMACEUTICAL AGENTS | WARNER-LAMBERT COMPANY (US) | 2001-04-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072533-A1 | Method of treating cartilage damage | COL2A1, COL1A1, GABRB1 | CYP1A2 1403/4885ALDH1A1 30/4885USP2 1071/4885 |
| US-20020161047-A1 | Method for preventing and treating visceral pain and gastrointestinal disorders | ALPI, VIP, SLC10A2 | CYP1A2 845/4885ALDH1A1 420/4885USP2 3321/4885 |
| US-20040266876-A1 | Method for preventing and treating visceral pain and gastrointestinal disorders | ALPI, VIP, SLC10A2 | CYP1A2 845/4885ALDH1A1 420/4885USP2 3321/4885 |
| US-20040152779-A1 | Bicyclic amino acids as pharmaceutical agents | AADAT, SLC1A2, BCAT1 | CYP1A2 1081/4885ALDH1A1 1224/4885USP2 4661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.